2,252 results match your criteria: "Henri-Mondor Hospital[Affiliation]"
Fam Pract
October 2024
Département de Médecine Générale, Faculté de Médecine, Université Paris-Est Créteil (UPEC), Créteil, France.
Background: In 2020, 19.2 million people were diagnosed with cancer, and nearly 10 million cancer patients died worldwide. An effective cancer care pathway must be based on coordination, multidisciplinarity, a personalized approach, and collaboration between stakeholders.
View Article and Find Full Text PDFArthritis Rheumatol
September 2024
Henri Mondor Hospital, Créteil, France, INSERM, Créteil, France, Paris Est Créteil University, Créteil, France, French National Agency for Medicines and Health Products Safety, Saint-Denis, France, Le Kremlin Bicêtre, France.
Eur J Radiol
June 2024
Memorial Sloan Kettering Cancer Center (MSK), Department of Radiology, 1275 York Avenue, New York, NY 10065, USA; Sorbonne University, Department of Radiology, Tenon Hospital, 4 rue de la Chine, 75020 Paris, France; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Clin Neuroradiol
December 2024
Department of Diagnostic and Interventional Neuroradiology, Erasme University Hospital, Brussels, Belgium.
Background: Optimal anesthetic strategy for the endovascular treatment of stroke is still under debate. Despite scarce data concerning anesthetic management for medium and distal vessel occlusions (MeVOs) some centers empirically support a general anesthesia (GA) strategy in these patients.
Methods: We conducted an international retrospective study of MeVO cases.
J Eur Acad Dermatol Venereol
September 2024
Department of Pediatric Dermatology, Hôpital Necker-Enfants Malades Hospital, APHP, Paris City University, Paris, France.
Polymers (Basel)
April 2024
Innovative Dental Materials and Interfaces Research Unit, Faculty of Dentistry, Université Paris Cité, 1 rue Maurice Arnoux, 92120 Montrouge, France.
The objective of this study was to detail the monomer composition of resin-based dental materials sold in the market in 2023 and to evaluate the proportion of bisphenol A (BPA)-derivatives in relation to their applications. A search on manufacturers' websites was performed to reference resin-based dental materials currently on the European market (including the European Union (EU) and United Kingdom (UK). Their monomer composition was determined using material-safety data sheets and was completed by a search on the PubMed database.
View Article and Find Full Text PDFCurr Oncol
April 2024
UOSA Interventional Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Background: Castleman disease (CD) is an uncommon benign lymphoproliferative disease characterized by hypervascular lymphoid hyperplasia. We present a unique case of unicentric CD of the parotid gland treated by preoperative direct puncture embolization.
Case Presentation: A 27-year-old female patient was admitted for a right neck mass.
Nat Rev Dis Primers
April 2024
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei/Linkou branches, and Chang Gung University, Taoyuan, Taiwan.
Sci Immunol
April 2024
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT).
View Article and Find Full Text PDFEur J Surg Oncol
June 2024
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore; Surgery Academic Clinical Programme, Duke-National University of Singapore Medical School, Singapore. Electronic address:
Redox Biol
June 2024
University Paris-Est Créteil, INSERM, IMRB, F-94010, Créteil, France. Electronic address:
Carbon monoxide (CO), a gaseous signaling molecule, has shown promise in preventing body weight gain and metabolic dysfunction induced by high fat diet (HFD), but the mechanisms underlying these effects are largely unknown. An essential component in response to HFD is the gut microbiome, which is significantly altered during obesity and represents a target for developing new therapeutic interventions to fight metabolic diseases. Here, we show that CO delivered to the gut by oral administration with a CO-releasing molecule (CORM-401) accumulates in faeces and enriches a variety of microbial species that were perturbed by a HFD regimen.
View Article and Find Full Text PDFIntroduction: Toxic gain-of-function () variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end-stage kidney disease. The identification of two variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.
View Article and Find Full Text PDFLancet Reg Health Eur
May 2024
Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Henri-Mondor Hospital (AP-HP), Créteil, France.
Background: Historically, sickle cell disease (SCD) patients experiencing frequent hospitalized vaso-occlusive crises (HVOC) have been associated with increased mortality, yet recent data reflecting the widespread use of hydroxyurea and advancements in disease management remain limited. Our study aims to assess the association between HVOC and mortality or severe complications in patients with SCD in this new treatment landscape.
Methods: This was a retrospective observational cohort study using the French national health data system.
Allergy
October 2024
ToxiTEN group of the ERN-skin.
Stem Cell Res
June 2024
Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, WA, Australia; Centre for Medical Research, University of Western Australia, QEII Medical Centre, Nedlands, WA, Australia.
RYR1 variants are the most common genetic cause of congenital myopathies, and typically cause central core disease (CCD) and/or malignant hyperthermia (MH). Here, we generated iPSC lines from two patients with CCD and MH caused by dominant RYR1 variants within the central region of the protein (p.Val2168Met and p.
View Article and Find Full Text PDFStem Cell Res
June 2024
Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, WA, Australia; Centre for Medical Research, University of Western Australia, QEII Medical Centre, Nedlands, WA, Australia.
RYR1 variants are a common cause of congenital myopathies, including multi-minicore disease (MmD) and central core disease (CCD). Here, we generated iPSC lines from two CCD patients with dominant RYR1 missense variants that affect the transmembrane (pore) and SPRY3 protein domains (p.His4813Tyr and p.
View Article and Find Full Text PDFContact Dermatitis
July 2024
Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.
Haematologica
August 2024
Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry, France; Institut universitaire de France (IUF).
Patients with sickle cell disease (SCD) display lower slope coefficients of the oxygen uptake (V̇O2) versus work rate (W) relationship (delineating an O2 uptake/demand mismatch) and a poor metabolic flexibility. Because endurance training improves the microvascular network and increases the activity of oxidative enzymes, including one involved in lipid oxidation, endurance training might improve the slope coefficient of the V̇O2 versus W curve and the metabolic flexibility of SCD patients. Endurance training may also contribute to improve patients' post-exercise cardiopulmonary and metabolic recovery.
View Article and Find Full Text PDFJ Invest Dermatol
October 2024
Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France. Electronic address:
Lancet Public Health
June 2024
Department of Dermatology, EpiDermE, Henri Mondor Hospital, Université Paris-Est Créteil, Créteil, France; Department of Dermatology, Université Paris-Est Créteil Val de Marne-Université Paris, Paris, France. Electronic address:
Background: Vitiligo is a chronic autoimmune disease characterised by depigmented skin patches, which can pose substantial psychosocial challenges particularly in individuals with dark skin tones. Despite its impact on quality of life, there is an absence of standardised global epidemiological data. We sought to address this gap with the present study.
View Article and Find Full Text PDFBackground: Recent randomized trials have shown the benefit of mechanical thrombectomy (MT) also in patients with an established large ischemic core.
Aims: The purpose of this study was to define baseline predictors of clinical outcome in patients with large vessel occlusion (LVO) in the anterior circulation and an Alberta Stroke Program Early CT score (ASPECTS) ⩽ 5, undergoing MT.
Material And Methods: The databases of 16 comprehensive stroke centers were retrospectively screened for patients with LVO and ASPECTS ⩽5 that received MT.
Eur Urol
July 2024
Department of Urology, Henri Mondor Hospital, University of Paris Est Créteil, Créteil, France.
J Neurointerv Surg
April 2024
Department of Interventional Neuroradiology, Sorbonne Université, APHP, Pitié-Salpêtrière Hospital, Paris, France.
Ann Dermatol Venereol
June 2024
Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France; Université Paris Est Créteil EpidermE, Créteil, France; Competence Center for Autoimmune Bullous Diseases MALIBUL, Henri-Mondor Hospital AP-HP, Créteil, France. Electronic address:
Background: Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients.
View Article and Find Full Text PDF